Genetic polymorphisms in Keap1 or Nrf2 further influence individual susceptibility to HTN and response to therapy, highlighting the need for personalized approaches (Begum and Lakshmanan, 2023). This evidence concerns the gene NFE2L2 and hypertensive disorder.